Patients’ Costs and Cost-Effectiveness of Tuberculosis Treatment in DOTS and Non-DOTS Facilities in Rio de Janeiro, Brazil

Página do item simplificado
dc.contributor.authorSteffen, Ricardo
dc.contributor.authorMenzies, Dick
dc.contributor.authorOxlade, Olivia
dc.contributor.authorPinto, Marcia
dc.contributor.authorCastro, Analia Zuleika de
dc.contributor.authorMonteiro, Paula
dc.contributor.authorTrajman, Anete
dc.date.accessioned2024-10-23T16:29:38Z
dc.date.available2024-10-23T16:29:38Z
dc.date.issued2010
dc.description.abstractBackground: Costs of tuberculosis diagnosis and treatment may represent a significant burden for the poor and for the health system in resource-poor countries. Objectives: The aim of this study was to analyze patients’ costs of tuberculosis care and to estimate the incremental cost- effectiveness ratio (ICER) of the directly observed treatment (DOT) strategy per completed treatment in Rio de Janeiro, Brazil. Methods: We interviewed 218 adult patients with bacteriologically confirmed pulmonary tuberculosis. Information on direct (out-of-pocket expenses) and indirect (hours lost) costs, loss in income and costs with extra help were gathered through a questionnaire. Healthcare system additional costs due to supervision of pill-intake were calculated considering staff salaries. Effectiveness was measured by treatment completion rate. The ICER of DOT compared to self-administered therapy (SAT) was calculated. Principal Findings: DOT increased costs during the treatment phase, while SAT increased costs in the pre-diagnostic phase, for both the patient and the health system. Treatment completion rates were 71% in SAT facilities and 79% in DOT facilities. Costs per completed treatment were US$ 194 for patients and U$ 189 for the health system in SAT facilities, compared to US$ 336 and US$ 726 in DOT facilities. The ICER was US$ 6,616 per completed DOT treatment compared to SAT. Conclusions: Costs incurred by TB patients are high in Rio de Janeiro, especially for those under DOT. The DOT strategy doubles patients’ costs and increases by fourfold the health system costs per completed treatment. The additional costs for DOT may be one of the contributing factors to the completion rates below the targeted 85% recommended by WHO.
dc.identifier.citationSteffen R, Menzies D, Oxlade O, Pinto M, de Castro AZ, Monteiro P, Trajman A. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLoS One. 2010 Nov 17;5(11):e14014. doi: 10.1371/journal.pone.0014014.
dc.identifier.otherDOI: 10.1371/journal.pone.0014014
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/525
dc.language.isoen
dc.publisherPLOS ONE
dc.subjectAdulten
dc.subjectAntitubercular Agents / economicsen
dc.subjectAntitubercular Agents / therapeutic use*en
dc.subjectBrazilen
dc.subjectCommunity Health Services / economicsen
dc.subjectCommunity Health Services / methods*en
dc.subjectCost-Benefit Analysisen
dc.subjectDirectly Observed Therapy / economicsen
dc.subjectDirectly Observed Therapy / methods*en
dc.subjectFemaleen
dc.subjectHealth Care Costsen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectSurveys and Questionnairesen
dc.subjectTreatment Outcomeen
dc.subjectTuberculosis / drug therapy*en
dc.titlePatients’ Costs and Cost-Effectiveness of Tuberculosis Treatment in DOTS and Non-DOTS Facilities in Rio de Janeiro, Brazil
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Steffen R et al_PLOS ONE.pdf
Tamanho:
210.51 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente